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Abstract
Medulloblastoma is the most common malignant brain
tumour in children and is a major cause of mortality and
morbidity, particularly in low- and middle-income
countries. It has been risk-stratified on the basis of clinical
(age, metastasis and extent of resection) and histological
subtypes (classic, desmoplastic and anaplastic). However,
recently medulloblastoma has been sub-grouped by using
a variety of different genomic approaches, such as gene
expression profiling, micro-ribonucleic acid profiling and
methylation array into 4 groups, namely Wingless, Sonic
hedgehog, Group 3 and Group 4. This new sub-grouping
has important therapeutic and prognostic implications.
After acute leukaemia, brain tumour is the second most
common malignancy in the paediatric age group. The
improvement in outcome of acute lymphoblastic
leukaemia in low- and middle-income countries reflects the
relative simplicity of diagnostic procedures and
management. Unlike leukaemia, the management of brain
tumours requires a complex multidisciplinary approach,
including neuro-radiologists, neurosurgeons with a
paediatric expertise, neuropathologists, radiation
oncologists and neuro-oncologists. In addition, the
equipment required for the diagnosis (magnetic resonance
imaging scan, histological, molecular and genetic
techniques) and the management (operating room,
radiation facilities) is a limiting factor in countries with
limited resources. In Pakistan, there are very few centres
able to treat children with brain tumours. The current
literature review was planned to provide an update on the
management of this tumour. 




Childhood medulloblastoma is the most common
malignant brain tumour. It arises in the posterior fossa and
accounts for 20-25% of all primary paediatric central
nervous system (CNS) tumours in high-income countries
(HICs).1 The most common age of presentation in children
is 3-10 years, and gender distribution has shown higher
incidence in boys. However, the incidence from low-income
countries (LICs) shows large variations ranging from 6.1%
to 49.4% of reported series of paediatric brain tumours. This
is likely due to multiple factors, including unavailability of
proper data and lack of multidisciplinary teams even in
tertiary care centres.2 It is also suspected that a number of
cases are not diagnosed.2 Poor socioeconomic status, late
diagnosis, and inaccessibility to treatment in most tertiary
centres countrywide are major factors of poor prognosis.
Although most countries with limited resources have
neurosurgical facilities, radiation equipments and
paediatric oncologic services, they often lack a
multidisciplinary team approach that is critical in the
management of this condition.3 There is a paucity of data
regarding the incidence, treatment modalities and the
outcome of children with brain tumours in low middle-
income countries (LMICs). The current literature review was
planned to provide recommendations for the treatment
outcomes of childhood medulloblastoma in LMICs.3
Methods
Published literature was collected and summarised on the
principles of multidisciplinary management of
medulloblastoma from 2010 to 2017. PubMed was used as
the resource database. A meta-narrative approach was
used to identify and understand how the studies were
conducted and conceptualised. Meta-narrative review has
helped n the formulation of treatment guidelines for LMICs.
Results
Of the 65 articles on childhood medulloblastoma reviewed,
33(50.7%) were helpful in makng recommendations
regarding diagnosis and treatment of the condition
published in the last 5 years. Early presentation, recognition
of signs and symptoms, availability of a formally trained
physician, multidisciplinary approach and tumour board
meetings in grouping with centres treating
medulloblastoma in high-income settings will help
standardise its clinical practice in LMICs.
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Management Guidelines
Histopathology
Medulloblastoma is a heterogeneous disease on the basis
of its various histological variants. Histologically, it is
divided into the classic type which is the most common
subtype; medulloblastoma with desmoplastic nodularity,
which is more common in infants and young adults,
medulloblastoma with extensive nodularity which is
exclusively seen in infants, and anaplastic and/or large cell
medulloblastoma. These four different histological
subtypes of medulloblastoma can be grouped into two
major pairs with many similar morphological features:
nodular desmoplastic tumours comprising desmoplastic /
nodular (D/N) and medulloblastoma with extensive
nodularity (MBEN) variants; and anaplastic
medulloblastoma overlapped with clear cell or large cell
tumours (Figure). These variants have significant clinical
utility on the management and outcomes: the
desmoplastic variant has a better outcome than classic or
anaplastic medulloblastomas in infants, and anaplastic
medulloblastoma fares poorly compared to classic or
desmoplastic tumours in both infants and children.4
Identification of the histological subtype before initiating
treatment is critical. This will guide the oncologist to choose
more intensive chemotherapy and higher dose of radiation
for patients with higher risk, or, conversely, to consider
standard or reduced dose radiation and maintenance
chemotherapy for patients with low or standard risk,
aiming to decrease treatment related morbidities.
Presentation
The most critical step in the management of
medulloblastoma is to establish a correct diagnosis.
Presenting sign and symptoms mainly depends on the site
of involvement, like in any brain tumour.5 Most of these
children present with signs of raised intracranial pressure
due to the blockage of the aqueduct of Sylvius. They,
2008
Vol. 70, No. 11, November 2020
Figure: Histological variants of medulloblastoma. a) | Classic medulloblastoma,. b) | D/N medulloblastoma  c) | MBEN tissue. d) an anaplastic medulloblastoma. e) | a large cell
medulloblastoma displaying the characteristic features of monomorphic cells with large nuclei and prominent nucleoli. (D/N, desmoplastic nodular; LCA, large
cell/anaplastic; MBEN, medulloblastoma with extensive nodularity).
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therefore, often present with severe continuous morning
headaches, recurrent projectile vomiting, neck pain and
blurred vision. Cerebellar deficits which include gait
problems and dysmetria can also be observed. As these
presenting symptoms may be relatively non-specific, delay
in diagnosis is frequent. In developing countries, we should
keep our mind open for these symptoms as it will help us
to diagnose these patients early and treat them in optimal
conditions.3
Molecular classification
Over the last 10 years, large cooperative multi-institutional
studies have been able to better characterise the biology
of childhood medulloblastoma with the help of genomic
and proteomic methods, mainly transcriptomic and
methylomic analytical methods. As a result,
medulloblastoma advanced genomic international
consortium (MAGIC) described four principal molecular
subgroups in medulloblastoma: Wingless, (WNT), Sonic
hedgehog (SHH), Group 3, and Group 4. WNT and SHH
tumours are marked by determining their specific
signalling pathway leading to an up-regulation of the WNT
and SHH pathways, respectively. The underlying genetic
drivers or pathways associated with Groups 3 and 4
medulloblastoma are less identified, although some
specific signatures have been described, like
photoreceptors and those pertaining to or affecting the
neurotransmitter gamma-aminobutyric acid (GABAergic)
in Group 3, and neuronal and glutaminergic in Group 4.
More studies are needed to better characterise these 2
subgroups.(6) When correlating clinical course with genetic
subtyping, the most important implication of molecular
classification in medulloblastoma is the prognosis, which
differs markedly across tumour subgroups with WNT
carrying the best outcome exceeding 90% with the current
standard therapy. By contrast, patient with Group 3
tumours have the prognosis with survival rates in the range
of 40-60%. Other subtypes SHH and Group 4 have an
intermediate event-free survival (EFS). The International
Society of Neuropathology (ISN) in one of its consensus
meetings recently recommended inclusion of molecular




It is the least common (10-15%), but the best studied
subgroup. Children with this subtype have the best
prognosis (>90% survival) compared to other subtypes.
Most patients present with localised (non-metastatic)
disease. WNT bedulloblastoma exhibits the nuclear
accumulation of β catenin in more than 90% of the
tumours. They further harbour mutations of CTNNB1 that
encodes for β catenin which explains the nuclear immune-
positivity observed.6,7 Another hallmark of WNT
medulloblastoma is the deletion of one copy of
chromosome 6. Both monosomy 6 and nuclear β catenin
accumulation are highly sensitive markers of this subtype.
Histologically, most WNT tumours have classic histological
features, but large cell/anaplastic (LCA) variants have been
reported in literature as well.8 Most patients are children,
particularly teenagers, and this subgroup is not seen in
infants and adults. Gender distribution has shown a female
predilection, unlike other subgroups which are more
common in boys. These tumours are typically located in the
cerebellar peduncle/ cerebellopontine angle cistern, and
their resection can be challenging. However, as the
prognosis is good, therefore it is recommended to treat
with reduced dose of craniospinal irradiation (CSI)
regardless of the extent of surgery, combined with
conventional chemotherapy. The 5-year overall survival is
excellent.7
SHH subtype 
SHH constitutes about 30% of all medulloblastoma. On
presentation about 15-20% may have metastatic disease.
Incidence is bimodal and this subtype affects infants and
young adults more frequently. It is less common in children,
where a specific variant associated with p53 mutation and
aggressive behaviour can be observed. Sonic Hedgehog
signalling pathways were first identified in patients with
Gorlin Syndrome, characterised by a germline mutation of
PTCH 1 (patched-1) tumour suppressor gene. SMO
(smoothened) and SUFU (Suppressor of fused) mutations
are the other genomic alterations associated with infantile
SHH. D/N histology is the most common histology
associated with SHH, but not all SHHs exhibit D/N
architecture; literature also depicted some association with
classic or LCA histology in SHH. Gender ratio revealed slight
male preponderance. Cerebellar hemisphere is the most
common site associated with SHH molecular subgroup.
Five-year overall survival is 75%, but the prognosis is
extremely poor in patients with p53 mutation (mutant
type) as it is commonly associated with Li-Fraumeni
syndrome.9,10
Group 3 subgroup
This subgroup accounts for 25% of all the medulloblastoma
and a large proportion of patients with Group 3 tumours
presents with metastatic disease at diagnosis.  This
subgroup is predominantly common in infants and pre-
schoolers. Children with Group 3 and metastatic disease
have the worst outcome with a 5-year survival rate in the
range of 50% or less.5 This subtype is not usually associated
with any specific germline mutation; only few somatic
genomic alterations MYC (MYC proto-oncogene) or OTX2
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(Orthodenticle homeobox-2) mutation in chromatin
protein encoded by SMARCA4 (SWI/SNF Related, Matrix
Associated, Actin Dependent Regulator Of Chromatin,
Subfamily A, Member 4), KMT 2D (Histone-lysine N-
methyltransferase 2)  and CHD 7 (Chromodomain-
helicase-DNA-binding protein 7 )  have recently been
identified.6,8 As far as the histology is concerned, Classic
architecture and LCA are the two histological subtypes
present in this subgroup. Males are affected twice as
frequently then females.10,11
Group 4 subgroup
This is the most common subtype across the four
subgroups (35%), and is present in all age groups except in
infants.5 Males outnumber females. Children aged 5-10
years are most frequently affected (median age: 9 years).
The prevalence of metastasis in Group 4 subgroup is 35%
at presentation. Although chromosome 17 abnormalities
are not exclusive of Group 4, they are the hallmark of this
subgroup. There is no specific germline mutation
associated with Group 4. Literature showed KDM6A (lysine
demethylase 6A) gene association in some of the Group 4
tumours that regulates the methylation of lysine 2.7 of
histone H (H3 K27).12 Classic and LCA are 2 histological
subtypes. Site of presentation includes midline and at the
4th ventricle. The 5-year overall survival is 75-85%.6,7
New Risk stratification
Cooperative clinical groups and consortia have traditionally
recognised three prognostic markers in childhood
medulloblastoma: age at diagnosis, postoperative residual
disease, and metastatic status. Patients aged ≤3 years,
leptomeningeal dissemination and postoperative residual
tumour ≥1.5 cm2, are assigned to have high-risk disease.
Children over 3-5 years of age with non-metastatic and fully
resected tumour or having minimal residual disease (<1.5
cm2) post-operatively fall into the standard risk category,
while children aged <3 years, those with metastatic disease
and with a postoperative residue >1.5cm2 are considered
high-risk.2 The clinical risk stratification, however, does not
take into account the underlying biology of the disease and
in particular the recent identification of 4 major
subgroups.13 In 2015, a consensus meeting was held in
Heidelberg, Germany, and data collected over the
preceding decade was reviewed.  A consensus was reached
to further refine the risk stratification in the context of
molecular subgrouping along with clinical features. An
updated risk stratification has been then established for
non-infant childhood medulloblastoma (ages 3–17). The
most recent risk stratification incorporates molecular
subtypes in risk groups and further classifies on the basis
of prognosis (Table 1).14 Patients are identified as low-risk
(>90% survival), average/standard risk (70–90% survival),
high-risk (50–75% survival), and very high risk (<50%
survival). The challenge in future is to gradually develop
new protocols adapted to this new classification and
explore targeted therapeutic approaches that integrate the
molecular subgrouping in clinical trials and helps to
improve the morbidities related to the intensive treatment
approaches of medulloblastoma.7,14,15
Imaging
The best diagnostic tool for any brain tumour is the MRI
without and with contrast, but, if not available, valuable
information can be obtained from computed tomography
(CT) scan of brain, which can identify the underlying
problem and contribute to referring the patient to a tertiary
care centre. On CT or MRI imaging, the tumour is
predominantly solid, located in the posterior fossa tumour,
commonly arising from the vermis and less commonly from
the cerebellar hemisphere.16 Ideally, a spinal MRI should be
done prior to surgery to detect metastatic disease. A recent
study correlated MRI characteristics, including tumour
location and enhancement pattern with specific molecular
subgroups of medulloblastoma. On MR imaging WNT
tumours usually arise in the cerebellopontine angle (CPA),
and the SHH most commonly involves the cerebellar
hemispheres, while Groupd 3 and 4 tumours are located in
the midline, filling the 4th ventricle with more
enhancement in Group 3 than in Group 4 which only shows
minimal enhancement.7
Initial management
Childhood medulloblastoma usually presents with signs of
raised intracranial pressure that require immediate
intervention. This involves gross total resection of tumour
or, if not possible, cerebrospinal fluid (CSF) diversion
procedure (ventriculo-peritoneal shunt or ventriculostomy)
2010
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Table-1: Risk stratification on the basis of molecular sub-grouping.
Risk stratification Molecular Sub-types
low-risk tumours -Wingless (WNT)* subgroup
-Non-metastatic subgroup Group 4 with
• chromosome 11 loss or chromosome 17 gain
Standard risk -SHH without MYCN*
-SHH (p53 wild type)
• Group 3 non metastatic a
• Group 4 non metastatic 
• with no loss of chromosome 11
High-risk group -Metastatic disease with 
• SHH* or 
• Group 4 molecular variant or 
• MYCN*-amplified SHH* medulloblastoma
Very high-risk -Metastatic disease in
• Group 3 or SHH* with TP53 (mutant) tumors
*SHH; Sonic hedgehog; *MYCN; MYC proto-Oncogene; *WNT; Wingless
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followed by tumour resection. Pre-operative
dexamethasone will help to reduce cerebral oedema.
Optimal management of medulloblastoma is
multidisciplinary, therefore early involvement of all the
clinicians, particularly neurosurgeon, pathologist, radiation
oncologist and paediatric neuro-oncologist, is critical as
soon as the child is admitted in a tertiary care centre. Final
decisions for management should be made preferably after
review by the multidisciplinary team (MDT). Due to the
complexity of the management and subsequent follow-up,
in most places, the paediatric oncologist is the designated
person who chairs the team. There should be a contact
person either from neurosurgery or paediatric oncology to
support patients and families at all stages of illness.17
Surgical guidelines
Gross total resection remains the first-line treatment for
medulloblastoma confined to the posterior fossa. The
management of patients with extensive metastatic disease
is more controversial. Advanced operative equipment,
better understanding of tumour biology and posterior
fossa anatomy and refined microsurgical techniques have
made it possible for neurosurgeons to plan gross total
resection in the majority of medulloblastoma cases, which
significantly helps to risk-stratify these patients in average
risk group, therefore improve their functional outcomes, by
using a lower dose of CSI. However, surgery should aim at
minimal morbidity, particularly when the tumour is
adherent to brainstem or cranial nerves. With attempts at
radical resections, the operative morbidity does increase,
in particular with a higher incidence of posterior fossa
mutism, but in experienced hands, the operative mortality
is still less than 1 per cent. The extent of tumour resection
has been shown to be better and the morbidity lower when
the surgery is performed by specialised paediatric
neurosurgeons, rather than by general neurosurgeons.17
Although gross surgical resection should remain the
standard of care, further resection of metastatic deposits is
not recommended when the risk of neurological morbidity
is high. Second-look surgery is always an option if there is
a large residual disease, which can be resected without
significant neurological morbidity. CSF cytology (collected
from a lumbar puncture at least 14 days after surgery,  but
preferable before surgery) should be analysed to complete
the metastatic workup.18 Perioperative steroids
(dexamethasone) help to reduce intracranial pressure. CSF
diversion with an extra-ventricular drain (EVD) can be
helpful in alleviating the hydrocephalus. However, insertion
of a ventriculoperitoneal shunt prior to tumour resection
is no longer recommended as the majority of patients will
not need a shunt following tumour resection. The standard
approach is through a midline sub-occipital craniectomy
by making a surgical corridor through the natural space in
between the cerebellar tonsils. Most of the
medulloblastoma tumours are soft and are easily suckable.
Every attempt should be made to limit the cerebellar
retraction but for superiorly extending tumours, or those
extending to the foramina of Luschka and Magendie, the
cerebellar vermis may require to be split, in which case the
inferior vermis is divided, sparing the superior vermis. Even
for large tumours, despite their size, excellent grey-white
differentiation allows an easy resection, even from the
foramina and the floor of fourth ventricle. Tumour adherent
to the floor should be dealt with with micro-dissection but
in case of difficulty, it is acceptable for some tumour to be
left behind. Intra-operative adjuncts, such as high
magnification microscope, CUSA (cavitron ultrasonic
surgical aspirator), high-quality bipolar and brainstem
monitoring, are all useful. Postoperatively, 20-30% of
children may eventually require a CSF diversion, either with
a third ventriculostomy or a ventriculoperitoneal shunt.19
Although some reports have pointed out the risk of shunt-
associated seeding, this occurrence is exceedingly low and
mostly seen when no chemotherapy is given. The post-
operative MRI should be carried out within 48 hours, as
post-operative changes will eventually interfere with
contrast enhancement and make interpretation of the
findings difficult. Apart from the risk of hydrocephalus,
post-operative complications include haemorrhage usually
from residual tumour, cerebellar swelling, new onset
neurological deficits, including those related to brainstem
swelling or injury, post-operative mutism, infection, etc.
Posterior fossa syndrome, also known as cerebellar mutism
syndrome, is associated with various signs and symptoms
including mutism, swallowing disturbances, cranial nerves
deficits, severe ataxia, decreased motor movement and
emotional lability. Recent follow-up studies have shown
that this complication has a serious impact on the neuro-
cognitive outcome of affected patients.3,17
Radiotherapy guidelines
Irradiation to the craniospinal axis with boost to the
primary tumour bed is currently the recommended post-
operative treatment for patients with average-risk
medulloblastoma. CSI with whole posterior fossa boost is
still the standard treatment for high-risk patients.
Radiotherapy should be started as soon as possible and not
later than 6 weeks after surgery as per International Society
of Paediatric Oncology (SIOP) recommendations.3 There is
evidence that delaying radiation treatment increases the
risk of relapse.20 Considering the known problems of
radiation waiting lists, late referrals and logistic issues in
most countries with limited resources, the SIOP Paediatric
Oncology in Developing Countries (PODC) adapted
treatment recommendations for standard-risk
medulloblastoma recommends doses used for the
2011
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management of high-risk medulloblastoma if the radiation
treatment starts after 7 weeks of tumour resection,
regardless of the risk group.21 However, this alternative has
a cost for the patient, as reduced dose or radiation from 36
Gy to 23.4 Gy to the craniospinal axis in patients with
standard-risk disease has shown decreased neurocognitive
and endocrine late effects without compromising their
progression-free survival.22 Radiation therapy for
medulloblastoma comprises irradiation of the craniospinal
axis, including the whole of brain, spinal cord and the
complete area of CSF flow. The field should cover the
complete thecal sac, including the exits of nerves at inter-
vertebral foramina for meningeal coverage, and the
cribriform plate. Three-dimensional conformal radiation
treatment (3D-CRT) is preferred over the conventional two-
dimensional planning, but it might not be available at all
centres. The initial craniospinal irradiation includes two
lateral fields to cover the whole brain. These fields are
matched with the posterior spinal field. The spine is
covered caudally till the junction of second and third sacral
vertebrae. A second spinal field is introduced for taller
children to cover the whole area of interest.18 Previously
considered the standard of care, the boost to the posterior
fossa has now been abandoned for a more focal boost to
the tumour bed in patients with non-metastatic,
completely resected medulloblastoma. This boost is
delivered with a 1-2cm margin using 3D-CRT. Intensity-
modulated radiation therapy (IMRT) may prove to be
beneficial for certain cases, but is not widely available in
the country. Boost can be done on the basis of bony
anatomy if 3D-CRT is not available, but the doses of organ
at risk like cochlea, cannot be ascertained.3,23 Total dose of
radiation depends upon the risk stratification done pre-
operatively. The recommended dose per fraction is 180 cGy
with 5-6 fractions per week. Hyper fractionation (2 x 1 Gy
or 2 x 1.3 Gy/day) has been used both in average-risk and
high-risk patients. However, this technique has not shown
any evidence of benefit. Standard-risk patients are treated
with 2340 cGy in 13 fractions to the craniospinal axis
followed by focal local radiation to the tumour bed of the
posterior fossa and total dose of 5400-5580 cGy in 17-18
more fractions. High-risk patients are prescribed CSI dose
being 3600 cGy in 20 fractions followed by boost of 1980
cGy to the whole posterior fossa. Standard-risk patients
who do not receive standard systemic therapy should be
treated like high-risk patients with a higher CSI dose of
3600 cGy.23,24 The boost to the tumour bed may also apply
to high-risk patients who do not show evidence of
metastatic disease (i.e. patients with residual >1.5 cm or
patients who start radiation late).25,26
Planning radiation to the craniospinal axis is a complex
process and treatment at specialised centres having peer-
reviewed practices is required for better outcome.23 This
does not only include availability of necessary equipment
but also trained and experience physicist, radiation
oncologist and radiation therapy technologist for careful
delivery of daily treatment.24 Quality assurance at each step
of planning and delivery of this specialised treatment
needs to be implemented. Correct daily positioning,
placement of shielding relevant to the bony anatomy and
matching the junction between cranial and spinal field and
both spinal fields are only some of the many important
concerns.23 Retrospective studies and prospective clinical
trials have suggested that patients treated at major centres
have a better outcome.27,28
Chemotherapy
Different combinations of chemotherapeutic regimens
have been shown to benefit the management of
medulloblastoma. The most commonly used
chemotherapy for patients >3 years of age with average-
risk disease consists of concomitant weekly vincristine
along with radiotherapy followed by chemotherapeutic
agents, including CCNU (Lomustine), cisplatin and
vincristine, or cyclophosphamide, cisplatin, and
vincristine.17 With such combination approaches, EFS is
over 80% in patients with average-risk medulloblastoma.26
The randomisation between cyclophosphamide and
lomustine in combination with cisplatine and vincristine
during maintenance did not show any difference in
survival, although incidence of febrile neutropenia with
cyclophosphamide was reported. This management
regimen has been successfully employed in various LMICs
and excellent survival was achieved for standard-risk
patients.3 Children >3 years, with high-risk
medulloblastoma are treated with intensive chemotherapy
during and post-radiation therapy.29 Pilot studies using
daily etoposide or a combination vincristine and
carboplatin during radiation, followed by maintenance
chemotherapy have been tested with promising results
and acceptable toxicity profile.30 Five-year EFS up to 70%
was reported with these approaches. However, the survival
benefit of such additions is still unknown. The results of
ACNS0332, a randomised study comparing craniospinal
irradiation with weekly vincristine administration and an
experimental arm with the addition of a daily infusion of
carboplatin as radiosensitiser are pending. A protocol using
craniospinal irradiation followed by an intensified cisplatin,
cyclophosphamide, vincristine, and etoposide regimen,
supported by peripheral stem cell rescue, has shown similar
outcomes.26,27 With the shortage of radiation equipments
and the difficulty to start radiotherapy in a timely manner,
some physicians in countries with limited resources may
consider the alternative of pre-radiation chemotherapy.
There is evidence that this option has a negative impact on
2012
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survival. The The GPOH HIT-91(German Society of Pediatric
Hematology and Oncology-Multicenter trial) randomised
pre-radiation “sandwich” intensive chemotherapy, versus
immediate radiotherapy with concomitant weekly
vincristine, followed by maintenance chemotherapy in
both arms, with vincristine, cisplatin and CCNU
(Lomustine). The “sandwich” chemotherapy group was
reported to have a higher incidence of severe neutropenia
resulting in subsequent radiotherapy interruptions and
decreased EFS. Some studies have also highlighted a high
incidence of disease progression on pre-radiation
chemotherapy. Therefore, it is a worldwide
recommendation to consider radiation upfront. There is an
ongoing debate regarding the benefit of weekly
administration of vincristine during radiotherapy and its
real impact on outcomes, particularly in teenagers who can
develop sensory neuropathies with this approach.3 Many
centres have also used varying low-intensity regimes with
some success depending on the level of clinical facilities
they may have. A Taiwanese study evaluated the results of
six cycles of cisplatin 20 mg/m2 and etoposide 40–60
mg/m2 for 5 days and reported an 8-year EFS of 65%.30 Six
cycles of carboplatin at a dose of 500–600 mg/m2/cycle,
alternating with six cycles of cyclophosphamide
750mg/m2, with vincristine has been used by an Egyptian
group, and both achieved an EFS of 70%. A regimen
consisting of cycles of cisplatin at 90mg/m2 with etoposide
150mg/m2 for 2 days alternating with cycles of vincristine
2mg/m2 and cyclophosphamide 1g/m2 for 2 days for a total
of 6 courses has been used with some success OS 44% by
Canan et al by the Turkey group but the hematological
toxicity of this protocol was significant.31
Long-term sequelae and follow-up
Survivors of CNS tumours in general experience late effects
resulting from the impact of the tumour itself and
subsequent therapies, including neurosurgery,
radiotherapy and chemotherapy. Susceptibility of
developing brain injury needs long-term surveillance
following treatment. Although there have been major
advances in the management of medulloblastoma in terms
of surgery, radiation, chemotherapy and supportive care,
the long-term toxicity of these treatments remains a
significant challenge and, as survival increases, these late
effects are becoming a major issue among long-term
survivors.32
The main long-term sequelae include the risk of
neurocognitive impairment, which includes memory
dysfunction, learning issues, slow processing speed,
psychological and emotional dysfunction. Risk factors
associated with neurocognitive deficits include young age,
postoperative mutism and higher dose of radiotherapy.
Endocrinopathies are extremely common among survivors,
as a result of craniospinal radiation. Fertility dysfunction
may also be secondary to chemotherapy. The occurrence
of secondary malignancies is not uncommon, in particular
meningioma that can have a long latency period up to 30
years. All these treatment-related morbidities can result in
moderate to severe disability and worsening of quality of
life. These have major implications in adult life with reduced
attainment of expected milestones, including education,
employment and independent living.33 Regular follow-up
visits are essential and should be emphasised. On every
visit a thorough physical exam should be done to evaluate
the morbidities of chemotherapy and radiation. These
include anthropometric monitoring and basal metabolic
index (BMI), examination of the skin in the radiation fields,
a search for thyroid nodules, signs of cerebellar
dysfunction, any visual field defects, hearing problems,
peripheral neuropathies and spine for scoliosis. Previous
spinal radiotherapy may affect spinal growth, induce
scoliosis, or cause an increased risk of degenerative arthritis
and osteoporosis; hence, early screening for osteoporosis
is recommended and any physical work which involves
lifting heavy weight should be avoided.9 A close
collaboration with an endocrinologist is mostly needed as
these patients are at high risk for growth hormone
deficiency, ACTH (Adrenocorticotropic hormone)
deficiency, hypothyroidism and metabolic syndrome. There
is high risk of secondary tumours and therefore, high index
of suspicion is needed for lesions in the radiotherapy field.
These survivors should be advised to avoid sunburn and
wearing a hat in bright sunlight.  They should have
audiometry every 1-2 years due to risk of hearing loss with
platinum compounds. An important point of concern
during the follow up visits is the mental health of the
patient which is a combined effect of radiation and
chemotherapy. Behaviour changes can be due to
prolonged absence from school, prolonged hospitalisation,
physical disabilities (short stature, obesity, alopecia,
endocrinopathies), learning and psychosocial difficulties.
The physician should enquire regarding schooling and
education and behaviour with timely referral to psychology
and social work team, if needed. These survivors are likely
to benefit from family counselling, psychology and
psychiatry consultation.34
Important point of consideration is that most of these
quality-of-life issues are closely related to the management
of the tumour itself. Proper risk stratification of the tumour
to identify patients that require high-dose radiation and
chemotherapy from those that can be treated with less
aggressive treatment on the basis of an appropriate staging
and molecular testing can help improve the late effects of
management. Safer radiation technique, like IMRT
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(Intensity modulated radiation therapy) may be used where
required. 
Observations required at the end of therapy to monitor the
long-term sequelae are critical (Table 2).35
Discussion
In HICs, individualisation of therapy for children with
medulloblastoma represents a major goal. In recent years,
histopathological and molecular disease features have
been identified with the potential to provide a more
refined stratification of disease.26 Unfortunately, these
specialised investigations are still not available in most
centres dealing with paediatric brain tumours in LMICs,
especially in Pakistan. Hence, risk stratification at the time
of diagnosis still remains elusive. 
Limited access to supportive care, poor baseline nutritional
status, concomitant infections or co-morbidities, and
unavailability of rehabilitation service, have a significant
influence in the treatment choices and outcomes in the
developing world. Therefore, guidelines and treatment
protocols developed in HICs may not be applicable in our
part of the world. The PODC committee of SIOP neuro-
oncology Working Group has, therefore, developed
guidelines for LMICs for the treatment of children with
standard-risk medulloblastoma.3 Another working PODC
group, with members of the Paediatric Oncology Radiation
society (PROS) have also developed adapted guidelines for
radiation in LMICs.22
These recommendations provide the opportunity to
develop a common strategy for the management of
medulloblastoma patients across Pakistan. Consistency in
the management between different centres will offer a
unique opportunity to collect national data and measure
the gap between Pakistan and other countries or
cooperative groups. 
One should keep in mind the complexity of the
management of this condition and the need to have a
perfect and timely interaction between different team
members. When a patient is initially seen in a neurosurgical
unit without a multidisciplinary paediatric neuro-oncology
programme, early referrals is critical and a peer review of
every single patient with a multi-disciplinary approach will
benefit us not only in maintaining a patient log, but also
help in the establishment of evidence-based guidelines
based on the response of therapy.
Conclusion
Despite the recent integration of biological markers in the
management of medulloblastoma, some questions still
need to be answered as to how we can incorporate these
molecular markers in LMICs where resources are scarce and
knowledge about this condition is still very limited. In this
context, multidisciplinary team management is the key.
Twinning between HICs and LMICs can improve the
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Table-2: Required Evaluations Following Completion of Protocol Therapy.
Evaluation 3 mon 4 mon 6 mon 8 mon 9 mon 12 mon 15 mon 16 mon 18 mon 20 mon 21 mon 2 yrs 2.5 yrs 3 yrs 3.5 yrs 4 yrs Annually At Relapse 
Disease 
Progression
History, Physical with X X X X X X X X X X X X X X X
Neurologic Exam
Liver Function, BUN, X X X X X X X X X X X X X X
Creatinine, Electrolytes 
(Ca, Mg), CBC
MRI of head X X X X X X X X X X X X X X X
(with contrast)
Spinal MRI X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X
(with contrast)‡
Lumbar CSF Cytology X$ X$ X$ X$ X$ X$ X$ X$ X$ X$ X
Audiogram X X X X X X X
Thyroid Function Evaluation X X X X X X
(Free T4 and TSH)
LH FSH, estradiol or X X X X X
testosterone
Serial Measurement of X X X X X X
Height (Stature)%
‡:Spinal MRI should include complete spine (cervical, thoracic, lumbar and sacral); %:Refer to endocrinologist if a growth below the 3rd percentile, drop in height percentile on growth grid, velocity 
<4 – 5 cm/year in childhood or lack of pubertal growth spurt; $ Obtain if initially positive. Patients with M1-M3 disease require the more frequent scans.
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outcome in these children.
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